Search

Your search keyword '"Jerkeman, M"' showing total 262 results
Start Over Author "Jerkeman, M" Publication Year Range Last 10 years
262 results on '"Jerkeman, M"'

5. Primary central nervous system lymphomas:EHA–ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆

Author

Ferreri, A. J.M., Illerhaus, G., Doorduijn, J. K., Auer, D. P., Bromberg, J. E.C., Calimeri, T., Cwynarski, K., Fox, C. P., Hoang-Xuan, K., Malaise, D., Ponzoni, M., Schorb, E., Soussain, C., Specht, L., Zucca, E., Buske, C., Jerkeman, M., Dreyling, M., Ferreri, A. J.M., Illerhaus, G., Doorduijn, J. K., Auer, D. P., Bromberg, J. E.C., Calimeri, T., Cwynarski, K., Fox, C. P., Hoang-Xuan, K., Malaise, D., Ponzoni, M., Schorb, E., Soussain, C., Specht, L., Zucca, E., Buske, C., Jerkeman, M., and Dreyling, M.

Published
2024

10. SOLUBLE MACROPHAGE MARKER SCD163 PREDICTS OUTCOME IN BOTH CHEMOIMMUNOTHERAPY AND TARGETED THERAPY TREATED MANTLE CELL LYMPHOMA

Author

Nikkarinen, A., primary, Lokhande, L., additional, Amini, R., additional, Jerkeman, M., additional, Porwit, A., additional, Molin, D., additional, Enblad, G., additional, Kolstad, A., additional, Räty, R., additional, Hutchings, M., additional, Weibull, C. E., additional, Hollander, P., additional, Ek, S., additional, and Glimelius, I., additional

Published
2023
Full Text
View/download PDF

12. Emerging role of SOX11 in mantle cell lymphoma

Author

Kuci V, Nordström L, Jerkeman M, and Ek S

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Abstract

Venera Kuci,1,2,* Lena Nordström,1,2,* Mats Jerkeman,3 Sara Ek1,2 1Department of Immunotechnology, Lund University, Lund, Sweden; 2CREATE Health, Lund University, Lund, Sweden; 3Department of Oncology, Lund University, Lund, Sweden *These authors contributed equally to this work Abstract: During recent years the neural transcription factor SOX11 has been established as an important biomarker for mantle cell lymphoma. SOX11 is both a diagnostic and prognostic antigen, and may potentially be used for treatment selection for younger patients, in relation to protocols including high dose chemotherapy. The molecular pathways involved are still not fully elucidated and, as SOX11 can interact with several co-transcription factors, functional assays need to be carefully designed to pinpoint SOX11-specific function in a defined cellular context. Furthermore, as SOX11 belongs to a large family of homologous proteins, analysis of SOX11 has been limited by the availability of specific antibodies for detection and pull-down. In this review, we discuss the emerging role of SOX11 in mantle cell lymphoma and discuss the potential impact in relation to tumorigenesis, diagnostics, prognostics, and therapy. Keywords: SOX11, mantle cell lymphoma, diagnostic

Published
2015

15. S209: PRIMARY RESULTS FROM THE PHASE 3 SHINE STUDY OF IBRUTINIB IN COMBINATION WITH BENDAMUSTINE-RITUXIMAB (BR) AND R MAINTENANCE AS A FIRST-LINE TREATMENT FOR OLDER PATIENTS WITH MANTLE-CELL LYMPHOMA

Author

Wang, M. L., primary, Jurczak, W., additional, Jerkeman, M., additional, Trotman, J., additional, Zinani, P. L., additional, Belada, D., additional, Boccomini, C., additional, Flinn, I. W., additional, Giri, P., additional, Goy, A., additional, Hamlin, P. A., additional, Hermine, O., additional, Hernández-Rivas, J.-Á., additional, Hong, X., additional, Kim, S. J., additional, Lewis, D., additional, Mishima, Y., additional, Özcan, M., additional, Perini, G. F., additional, Pocock, C., additional, Song, Y., additional, Spurgeon, S. E., additional, Storring, J. M., additional, Walewski, J., additional, Zhu, J., additional, Qin, R., additional, Henninger, T., additional, Deshpande, S., additional, Howes, A., additional, Le Gouill, S., additional, and Dreyling, M., additional

Published
2022
Full Text
View/download PDF

16. P1264: HEMATOPOIETIC CLONES WITH TP53 MUTATIONS EXPAND IN PATIENTS WITH MCL DURING LENALIDOMIDE-BASED THERAPY

Author

Husby, S., primary, Bæch-Laursen, C., additional, Favero, F., additional, Jespersen, J. S., additional, Eskelund, C. W., additional, Hutchings, M., additional, Pedersen, L. B., additional, Niemann, C. U., additional, Weischenfeldt, J., additional, Geisler, C., additional, Räty, R., additional, Larsen, T. S., additional, Kolstad, A., additional, Jerkeman, M., additional, and Grønbæk, K., additional

Published
2022
Full Text
View/download PDF

18. High-risk subtypes of chronic lymphocytic leukemia are detectable as early as 16 years prior to diagnosis

Author

Kolijn, P.M. Hosnijeh, F.S. Späth, F. Hengeveld, P.J. Agathangelidis, A. Saleh, M. Casabonne, D. Benavente, Y. Jerkeman, M. Agudo, A. Barricarte, A. Besson, C. Sánchez, M.-J. Chirlaque, M.-D. Masala, G. Sacerdote, C. Grioni, S. Schulze, M.B. Nieters, A. Engelfriet, P. Hultdin, M. McKay, J.D. Vermeulen, R.C.H. Langerak, A.W.

Subjects
immune system diseases, hemic and lymphatic diseases
Abstract

Chronic lymphocytic leukemia (CLL) is preceded by monoclonal B-cell lymphocytosis (MBL), a CLL precursor state with a prevalence of up to 12% in aged individuals; however, the duration of MBL and the mechanisms of its evolution to CLL remain largely unknown. In this study, we sequenced the B-cell receptor (BcR) immunoglobulin heavy chain (IGH) gene repertoire of 124 patients with CLL and 118 matched controls in blood samples taken up to 22 years prior to diagnosis. Significant skewing in the BcR IGH gene repertoire was detected in the majority of patients, even before the occurrence of lymphocytosis and irrespective of the clonotypic IGH variable gene somatic hypermutation status. Furthermore, we identified dominant clonotypes belonging to major stereotyped subsets associated with poor prognosis up to 16 years before diagnosis in 14 patients with CLL. In 22 patients with longitudinal samples, the skewing of the BcR IGH gene repertoire increased significantly over time to diagnosis or remained stable at high levels. For 14 of 16 patients with available samples at diagnosis, the CLL clonotype was already present in the prediagnostic samples. Overall, our data indicate that the preclinical phase of CLL could be longer than previously thought, even in adverse-prognostic cases. © 2022 American Society of Hematology

Published
2022

19. IMPACT OF DIFFERENT INDUCTION REGIMENS ON THE OUTCOME OF PRIMARY MEDIASTINAL B CELL LYMPHOMA IN THE PROSPECTIVE IELSG 37 TRIAL

Author

Martelli, M., primary, Zucca, E., additional, Botto, B., additional, Kryachok, I., additional, Ceriani, L., additional, Balzarotti, M., additional, Tucci, A., additional, Cabras, M. G., additional, Zilioli, V. R., additional, Rusconi, C., additional, Angrilli, F., additional, Arcaini, L., additional, Iwanicka, A. Dabrowska, additional, Ferreri, A.J.M., additional, Merli, F., additional, Zhao, W., additional, Hodgson, D., additional, Ionescu, C., additional, Fosså, A., additional, Cwynarski, K., additional, Mikhaeel, G., additional, Jerkeman, M., additional, Janikova, A., additional, Hüttmann, A., additional, Ciccone, G., additional, Metser, U., additional, Barrington, S., additional, Malkowski, B., additional, Versari, A., additional, Esposito, F., additional, Cozens, K., additional, Ielmini, N., additional, Ricardi, R., additional, Cavalli, F., additional, Johnson, P., additional, and Davies, A., additional

Published
2021
Full Text
View/download PDF

20. HIGH RISK AGGRESSIVE B‐CELL LYMPHOMA ON THE LIQUID BIOPSY

Author

Meriranta, L, primary, Alkodsi, A, additional, Pasanen, A, additional, Lepistö, M, additional, Blaker, Y. N, additional, Jørgensen, J, additional, Mapar, P, additional, Björkholm, M, additional, Jerkeman, M, additional, Holte, H, additional, Pitkänen, E, additional, Ellonen, P, additional, and Leppä, S, additional

Published
2021
Full Text
View/download PDF

21. Association between anthropometry and lifestyle factors and risk of B-cell lymphoma: An exposome-wide analysis

Author

Saberi Hosnijeh, F, Casabonne, D, Nieters, A, Solans, M, Naudin, S, Ferrari, P, Mckay, JD, Benavente, Y, Weiderpass, E, Freisling, H, Severi, G, Boutron Ruault, M-C, Besson, C, Agnoli, C, Masala, G, Sacerdote, C, Tumino, R, Huerta, JM, Amiano, P, Rodriguez-Barranco, M, Bonet, C, Barricarte, A, Christakoudi, S, Knuppel, A, Bueno-de-Mesquita, B, Schulze, MB, Kaaks, R, Canzian, F, Spath, F, Jerkeman, M, Rylander, C, Tjonneland, A, Olsen, A, Borch, KB, Vermeulen, R, Saberi Hosnijeh, F, Casabonne, D, Nieters, A, Solans, M, Naudin, S, Ferrari, P, Mckay, JD, Benavente, Y, Weiderpass, E, Freisling, H, Severi, G, Boutron Ruault, M-C, Besson, C, Agnoli, C, Masala, G, Sacerdote, C, Tumino, R, Huerta, JM, Amiano, P, Rodriguez-Barranco, M, Bonet, C, Barricarte, A, Christakoudi, S, Knuppel, A, Bueno-de-Mesquita, B, Schulze, MB, Kaaks, R, Canzian, F, Spath, F, Jerkeman, M, Rylander, C, Tjonneland, A, Olsen, A, Borch, KB, and Vermeulen, R

Abstract

To better understand the role of individual and lifestyle factors in human disease, an exposome-wide association study was performed to investigate within a single-study anthropometry measures and lifestyle factors previously associated with B-cell lymphoma (BCL). Within the European Prospective Investigation into Cancer and nutrition study, 2402 incident BCL cases were diagnosed from 475 426 participants that were followed-up on average 14 years. Standard and penalized Cox regression models as well as principal component analysis (PCA) were used to evaluate 84 exposures in relation to BCL risk. Standard and penalized Cox regression models showed a positive association between anthropometric measures and BCL and multiple myeloma/plasma cell neoplasm (MM). The penalized Cox models additionally showed the association between several exposures from categories of physical activity, smoking status, medical history, socioeconomic position, diet and BCL and/or the subtypes. PCAs confirmed the individual associations but also showed additional observations. The PC5 including anthropometry, was positively associated with BCL, diffuse large B-cell lymphoma (DLBCL) and MM. There was a significant positive association between consumption of sugar and confectionary (PC11) and follicular lymphoma risk, and an inverse association between fish and shellfish and Vitamin D (PC15) and DLBCL risk. The PC1 including features of the Mediterranean diet and diet with lower inflammatory score showed an inverse association with BCL risk, while the PC7, including dairy, was positively associated with BCL and DLBCL risk. Physical activity (PC10) was positively associated with DLBCL risk among women. This study provided informative insights on the etiology of BCL.

Published
2021

22. Multicohort Study of Conditional Survival and Cause of Death After Achieving Event‐Free Survival at 24 Months (EFS24) in Patients With Mantle Cell Lymphoma (MCL).

Author

Wang, Y., Larson, M. C., Ekberg, S., Smedby, K. E., Zhao, E. J., Gerrie, A. S., Farooq, U., Maurer, M. J., Paludo, J., Nowakowski, G. S., Habermann, T. M., Albertsson‐Lindblad, A., Glimelius, I., Link, B. K., Diego, V., Jerkeman, M., and Cerhan, J. R.

Subjects
MANTLE cell lymphoma, AFTERLIFE
Abstract

However, in Era M2, patients achieving EFS24 had similar OS compared to the general population (SMR = 1.35, 95% CI: 0.83-2.09), and lymphoma was no longer the leading cause of death (Figure 1 B&E). Multicohort Study of Conditional Survival and Cause of Death After Achieving Event-Free Survival at 24 Months (EFS24) in Patients With Mantle Cell Lymphoma (MCL) In Era M1, patients achieving EFS24 still had inferior OS compared to the general population (SMR = 2.81, 95% CI: 1.98-3.88), and lymphoma remained the leading cause of death. [Extracted from the article]

Published
2023
Full Text
View/download PDF

26. Inflammatory potential of diet and risk of lymphoma in the European Prospective Investigation into Cancer and Nutrition

Author

Solans, M. Benavente, Y. Saez, M. Agudo, A. Jakszyn, P. Naudin, S. Hosnijeh, F.S. Gunter, M. Huybrechts, I. Ferrari, P. Besson, C. Mahamat-Saleh, Y. Boutron-Ruault, M.-C. Kühn, T. Kaaks, R. Boeing, H. Lasheras, C. Sánchez, M.-J. Amiano, P. Chirlaque, M.D. Ardanaz, E. Schmidt, J.A. Vineis, P. Riboli, E. Trichopoulou, A. Karakatsani, A. Valanou, E. Masala, G. Agnoli, C. Tumino, R. Sacerdote, C. Mattiello, A. Skeie, G. Weiderpass, E. Jerkeman, M. Dias, J.A. Späth, F. Nilsson, L.M. Dahm, C.C. Overvad, K. Petersen, K.E.N. Tjønneland, A. de Sanjose, S. Vermeulen, R. Nieters, A. Casabonne, D.

Subjects
hemic and lymphatic diseases
Abstract

Introduction: Chronic inflammation plays a critical role in lymphomagenesis and several dietary factors seem to be involved its regulation. The aim of the current study was to assess the association between the inflammatory potential of the diet and the risk of lymphoma and its subtypes in the European Investigation into Cancer and Nutrition (EPIC) study. Methods: The analysis included 476,160 subjects with an average follow-up of 13.9 years, during which 3,136 lymphomas (135 Hodgkin lymphoma (HL), 2606 non-Hodgkin lymphoma (NHL) and 395 NOS) were identified. The dietary inflammatory potential was assessed by means of an inflammatory score of the diet (ISD), calculated using 28 dietary components and their corresponding inflammatory weights. The association between the ISD and lymphoma risk was estimated by hazard ratios (HR) and 95% confidence intervals (CI) calculated by multivariable Cox regression models adjusted for potential confounders. Results: The ISD was not associated with overall lymphoma risk. Among lymphoma subtypes, a positive association between the ISD and mature B-cell NHL (HR for a 1-SD increase: 1.07 (95% CI 1.01; 1.14), p trend = 0.03) was observed. No statistically significant association was found among other subtypes. However, albeit with smaller number of cases, a suggestive association was observed for HL (HR for a 1-SD increase = 1.22 (95% CI 0.94; 1.57), p trend 0.13). Conclusions: Our findings suggested that a high ISD score, reflecting a pro-inflammatory diet, was modestly positively associated with the risk of B-cell lymphoma subtypes. Further large prospective studies on low-grade inflammation induced by diet are warranted to confirm these findings. © 2019, Springer-Verlag GmbH Germany, part of Springer Nature.

Published
2020

27. Healthy lifestyle and the risk of lymphoma in the European Prospective Investigation into Cancer and Nutrition study

Author

Naudin, S. Solans Margalef, M. Saberi Hosnijeh, F. Nieters, A. Kyrø, C. Tjønneland, A. Dahm, C.C. Overvad, K. Mahamat-Saleh, Y. Besson, C. Boutron-Ruault, M.-C. Kühn, T. Canzian, F. Schulze, M.B. Peppa, E. Karakatsani, A. Trichopoulou, A. Sieri, S. Masala, G. Panico, S. Tumino, R. Ricceri, F. Chen, S.L.F. Barroso, L.L. Huerta, J.M. Sánchez, M.-J. Ardanaz, E. Menéndez, V. Amiano Exezarreta, P. Spaeth, F. Jerkeman, M. Jirstom, K. Schmidt, J.A. Aune, D. Weiderpass, E. Riboli, E. Vermeulen, R. Casabonne, D. Gunter, M. Brennan, P. Ferrari, P.

Subjects
immune system diseases, hemic and lymphatic diseases
Abstract

Limited evidence exists on the role of modifiable lifestyle factors on the risk of lymphoma. In this work, the associations between adherence to healthy lifestyles and risks of Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) were evaluated in a large-scale European prospective cohort. Within the European Prospective Investigation into Cancer and Nutrition (EPIC), 2,999 incident lymphoma cases (132 HL and 2,746 NHL) were diagnosed among 453,808 participants after 15 years (median) of follow-up. The healthy lifestyle index (HLI) score combined information on smoking, alcohol intake, diet, physical activity and BMI, with large values of HLI expressing adherence to healthy behavior. Cox proportional hazards models were used to estimate lymphoma hazard ratios (HR) and 95% confidence interval (CI). Sensitivity analyses were conducted by excluding, in turn, each lifestyle factor from the HLI score. The HLI was inversely associated with HL, with HR for a 1-standard deviation (SD) increment in the score equal to 0.78 (95% CI: 0.66, 0.94). Sensitivity analyses showed that the association was mainly driven by smoking and marginally by diet. NHL risk was not associated with the HLI, with HRs for a 1-SD increment equal to 0.99 (0.95, 1.03), with no evidence for heterogeneity in the association across NHL subtypes. In the EPIC study, adherence to healthy lifestyles was not associated with overall lymphoma or NHL risk, while an inverse association was observed for HL, although this was largely attributable to smoking. These findings suggest a limited role of lifestyle factors in the etiology of lymphoma subtypes. © 2020 UICC

Published
2020

28. ESMO Guidelines: Cancer patient management during the COVID-19 pandemic

Author

Aapro, M., Addeo, A., Acierto, P., Balermpas, P., Berg, T., Berghoff, A., Betella, I., Blay, J. -Y., Bosetti, D. G., Bossi, P., Bouchaab, H., Brandt, J., Buske, C., Caraceni, A., Cardoso, F., Carles, J., Catanese, S., Cherny, N., Colombo, I., Colombo, N., Cortes, J., Criscitiello, C., Curigliano, G., de Azambuja, E., Delagoge, S., Del Grande, M., De Santis, M., Douillard, J. -Y., Dummer, R., Dziadziuszko, R., Escudier, B., Fizazi, K., Fleitas, T., Franceschi, E., Hoeller, C., Gillessen, S., Gonzalez Martin, A., Gralla, R., Grigorescu, A., Gronchi, A., Hassan, A., Hui, D., Jerkeman, M., Jones, R., Jordan, K., Keilholz, U., Kreye, G., Ledermann, J., Loibl, S., Lordick, F., Lorigan, P., Loriot, Y., Machiels, J. -P., Broto, J. M., Mei, U., Michielin, O., Mori, M., Multinu, F., Paluch-Shimon, S., Parker, C., Passaro, A., Pentheroudakis, G., Peters, S., Piazza, C., Porta, C., Powles, T., Preusser, M., Reck, M., Ripamonti, C., Rubach, M., Rukhadze, T., Schmidinger, M., Sensus-Konefka, E., Sessa, C., Shaulov, A., Stacchiotti, S., Stevens, A. -M., Stintzing, S., Szturz, P., Trapani, D., van Akkooi, A., Vecchione, L., van Bommel, F., Vogl, U., Von Garnier, C., Weller, M., Wood, J., Zaccarelli, E., and Zimmermann, C.

Published
2020

29. Association between anthropometry and lifestyle factors and risk of B-cell lymphoma: An exposome-wide analysis

Author

Saberi Hosnijeh, F. (Fatemeh), Casabonne, D. (Delphine), Nieters, A. (Alexandra), Solans, M. (Marta), Naudin, S. (Sabine), Ferrari, P. (Pietro), Mckay, J.D. (James D.), Benavente, Y. (Yolanda), Weiderpass, E. (Elisabete), Freisling, H. (Heinz), Severi, G. (Gianluca), Boutron Ruault, M.-C. (Marie-Christine), Besson, C. (Caroline), Agnoli, C. (Claudia), Masala, G. (Giovanna), Sacerdote, C. (Carlotta), Tumino, R. (Rosario), Huerta, J.M. (José María), Amiano, P. (Pilar), Rodriguez-Barranco, M. (Miguel), Bonet, C. (Catalina), Barricarte, A. (Aurelio), Christakoudi, S. (Sofia), Knuppel, A. (Anika), Bueno-de-Mesquita, B. (Bas), Schulze, M.B. (Matthias), Kaaks, R. (Rudolf), Canzian, F. (Federico), Späth, F. (Florentin), Jerkeman, M. (Mats), Rylander, C. (Charlotta), Tjønneland, A. (Anne), Olsen, A. (Anja), Borch, K.B. (Kristin Benjaminsen), Vermeulen, R. (Roel), Saberi Hosnijeh, F. (Fatemeh), Casabonne, D. (Delphine), Nieters, A. (Alexandra), Solans, M. (Marta), Naudin, S. (Sabine), Ferrari, P. (Pietro), Mckay, J.D. (James D.), Benavente, Y. (Yolanda), Weiderpass, E. (Elisabete), Freisling, H. (Heinz), Severi, G. (Gianluca), Boutron Ruault, M.-C. (Marie-Christine), Besson, C. (Caroline), Agnoli, C. (Claudia), Masala, G. (Giovanna), Sacerdote, C. (Carlotta), Tumino, R. (Rosario), Huerta, J.M. (José María), Amiano, P. (Pilar), Rodriguez-Barranco, M. (Miguel), Bonet, C. (Catalina), Barricarte, A. (Aurelio), Christakoudi, S. (Sofia), Knuppel, A. (Anika), Bueno-de-Mesquita, B. (Bas), Schulze, M.B. (Matthias), Kaaks, R. (Rudolf), Canzian, F. (Federico), Späth, F. (Florentin), Jerkeman, M. (Mats), Rylander, C. (Charlotta), Tjønneland, A. (Anne), Olsen, A. (Anja), Borch, K.B. (Kristin Benjaminsen), and Vermeulen, R. (Roel)

Abstract

To better understand the role of individual and lifestyle factors in human disease, an exposome-wide association study was performed to investigate within a single-study anthropometry measures and lifestyle factors previously associated with B-cell lymphoma (BCL). Within the European Prospective Investigation into Cancer and nutrition study, 2402 incident BCL cases were diagnosed from 475 426 participants that were followed-up on average 14 years. Standard and penalized Cox regression models as well as principal component analysis (PCA) were used to evaluate 84 exposures in relation to BCL risk. Standard and penalized Cox regression models showed a positive association between anthropometric measures and BCL and multiple myeloma/plasma cell neoplasm (MM). The penalized Cox models additionally showed the association between several exposures from categories of physical activity, smoking status, medical history, socioeconomic position, diet and BCL and/or the subtypes. PCAs confirmed the individual a

Published
2020
Full Text
View/download PDF

30. Reproductive Factors, Exogenous Hormone Use, and Risk of B-Cell Non-Hodgkin Lymphoma in a Cohort of Women from the European Prospective Investigation into Cancer and Nutrition

Author

Costas, L. Lujan-Barroso, L. Benavente, Y. Allen, N.E. Amiano, P. Ardanaz, E. Besson, C. Boeing, H. Bueno-De-Mesquita, B. Cervenka, I. Fortner, R.T. Fournier, A. Gunter, M. Harlid, S. Huerta, J.M. Jerkeman, M. Jirström, K. Kaaks, R. Karakatsani, A. Khaw, K.-T. Kotanidou, A. Lund, E. Masala, G. Mattiello, A. Melin, B. Menéndez, V. Murphy, N. Nieters, A. Overvad, K. Riboli, E. Sacerdote, C. Sánchez, M.-J. Schmidt, J.A. Sieri, S. Tjønneland, A. Trichopoulou, A. Tumino, R. Vermeulen, R. Weiderpass, E. De Sanjosé, S. Agudo, A. Casabonne, D.

Abstract

The role of hormonal factors in the etiology of lymphoid neoplasms remains unclear. Previous studies have yielded conflicting results, have lacked sufficient statistical power to assess many lymphoma subtypes, or have lacked detailed information on relevant exposures. Within the European Prospective Investigation Into Cancer and Nutrition cohort, we analyzed comprehensive data on reproductive factors and exogenous hormone use collected at baseline (1992-2000) among 343,458 women, including data on 1,427 incident cases of B-cell non-Hodgkin lymphoma (NHL) and its major subtypes identified after a mean follow-up period of 14 years (through 2015). We estimated hazard ratios and 95% confidence intervals using multivariable proportional hazards modeling. Overall, we observed no statistically significant associations between parity, age at first birth, breastfeeding, oral contraceptive use, or ever use of postmenopausal hormone therapy and risk of B-cell NHL or its subtypes. Women who had undergone surgical menopause had a 51% higher risk of B-cell NHL (based on 67 cases) than women with natural menopause (hazard ratio = 1.51, 95% confidence interval: 1.17, 1.94). Given that this result may have been due to chance, our results provide little support for the hypothesis that sex hormones play a role in lymphomagenesis. © The Author(s) 2018.

Published
2019

31. Adherence to the mediterranean diet and lymphoma risk in the european prospective investigation into cancer and nutrition

Author

Solans, M. Benavente, Y. Saez, M. Agudo, A. Naudin, S. Hosnijeh, F.S. Noh, H. Freisling, H. Ferrari, P. Besson, C. Mahamat-Saleh, Y. Boutron-Ruault, M.-C. Kühn, T. Kaaks, R. Boeing, H. Lasheras, C. Rodríguez-Barranco, M. Amiano, P. Huerta, J.M. Barricarte, A. Schmidt, J.A. Vineis, P. Riboli, E. Trichopoulou, A. Bamia, C. Peppa, E. Masala, G. Agnoli, C. Tumino, R. Sacerdote, C. Panico, S. Skeie, G. Weiderpass, E. Jerkeman, M. Ericson, U. Späth, F. Nilsson, L.M. Dahm, C.C. Overvad, K. Bolvig, A.K. Tjønneland, A. de Sanjose, S. Buckland, G. Vermeulen, R. Nieters, A. Casabonne, D.

Abstract

There is a growing evidence of the protective role of the Mediterranean diet (MD) on cancer. However, no prospective study has yet investigated its influence on lymphoma. We evaluated the association between adherence to the MD and risk of lymphoma and its subtypes in the European Prospective Investigation into Cancer and Nutrition (EPIC) study. The analysis included 476,160 participants, recruited from 10 European countries between 1991 and 2001. Adherence to the MD was estimated through the adapted relative MD (arMED) score excluding alcohol. Cox proportional hazards regression models were used while adjusting for potential confounders. During an average follow-up of 13.9 years, 3,136 lymphomas (135 Hodgkin lymphoma [HL], 2,606 non-HL and 395 lymphoma not otherwise specified) were identified. Overall, a 1-unit increase in the arMED score was associated with a 2% lower risk of lymphoma (95% CI: 0.97; 1.00, p-trend = 0.03) while a statistically nonsignificant inverse association between a high versus low arMED score and risk of lymphoma was observed (hazard ratio [HR]: 0.91 [95% CI 0.80; 1.03], p-trend = 0.12). Analyses by lymphoma subtype did not reveal any statistically significant associations. Albeit with small numbers of cases (N = 135), a suggestive inverse association was found for HL (HR 1-unit increase = 0.93 [95% CI: 0.86; 1.01], p-trend = 0.07). However, the study may have lacked statistical power to detect small effect sizes for lymphoma subtype. Our findings suggest that an increasing arMED score was inversely related to the risk of overall lymphoma in EPIC but not by subtypes. Further large prospective studies are warranted to confirm these findings. © 2018 UICC

Published
2019

33. EARLY PROGRESSION OF MANTLE CELL LYMPHOMA DEPICTS A HIGH-RISK DISEASE WITH POOR RESPONSE TO SUBSEQUENT THERAPIES AND A DISMAL OUTCOME

Author

Eskelund, C.W., primary, Kolstad, A., additional, Glimelius, I., additional, Räty, R., additional, Gjerdrum, L.R., additional, Sonnevi, K., additional, Josefsson, P., additional, Nilsson-Ehle, H., additional, Bentzen, H., additional, Fagerli, U., additional, Kuittinen, O., additional, Haaber, J., additional, Pedersen, L.B., additional, Larsen, M.T., additional, Geisler, C.H., additional, Hutchings, M., additional, Jerkeman, M., additional, and Grønbaek, K., additional

Published
2019
Full Text
View/download PDF

34. EVOLUTION OF CLONAL HEMATOPOIESIS IN MANTLE CELL LYMPHOMA PATIENTS BEFORE, DURING, AND AFTER INDUCTION CHEMOTHERAPY AND AUTOLOGOUS STEM CELL TRANSPLANTATION

Author

Husby, S., primary, Eskelund, C.W., additional, Favero, F., additional, Rodriguez-Gonzalez, F.G., additional, Kolstad, A., additional, Pedersen, L.B., additional, Räty, R., additional, Geisler, C.H., additional, Jerkeman, M., additional, Weischenfeldt, J., additional, and Grønbaek, K., additional

Published
2019
Full Text
View/download PDF

35. YOUNG HIGH RISK PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA INCLUDING BCL-2/MYC DOUBLE HIT LYMPHOMAS BENEFIT FROM DOSE-DENSE IMMUNOCHEMOTHERAPY WITH EARLY CNS PROPHYLAXIS

Author

Leppä, S., primary, Jørgensen, J., additional, Tierens, A., additional, Meriranta, L., additional, Østlie, I., additional, Brown, P., additional, Fagerli, U., additional, Larsen, T.S., additional, Mannisto, S., additional, Munksgaard, L., additional, Maisenhølder, M., additional, Vasala, K., additional, Meyer, P., additional, Jerkeman, M., additional, Björkholm, M., additional, Fluge, Ø., additional, Jyrkkiö, S., additional, Ralfkiaer, E., additional, Spetalen, S., additional, Karjalainen-Lindsberg, M., additional, and Holte, H., additional

Published
2019
Full Text
View/download PDF

36. PHASE 1/2A CLINICAL TRIALS OF BI-1206, A MONOCLONAL ANTIBODY TO FCΓRIIB, ADMINISTERED AS A SINGLE AGENT OR IN COMBINATION WITH RITUXIMAB IN SUBJECTS WITH B-CELL MALIGNANCIES

Author

Karlsson, I., primary, Traub, S., additional, Järås, K., additional, Edwards, D., additional, Gramming, E., additional, Lindell Andersson, M., additional, To, Y., additional, Mårtensson, L., additional, Teige, I., additional, Acton, G., additional, Dyer, M.J., additional, Radford, J., additional, Collins, G.P., additional, Jerkeman, M., additional, Frendéus, B., additional, McAllister, A., additional, and Davies, A., additional

Published
2019
Full Text
View/download PDF

38. Impact of comorbidity on disease characteristics, treatment intent and outcome in diffuse large B-cell lymphoma : a Swedish lymphoma register study

Author

Wasterlid, T., Mohammadi, M., Smedby, K. E., Glimelius, Ingrid, Jerkeman, M., Bottai, M., Eloranta, S., Wasterlid, T., Mohammadi, M., Smedby, K. E., Glimelius, Ingrid, Jerkeman, M., Bottai, M., and Eloranta, S.

Abstract

Background Comorbidity impacts overall survival amongst patients with diffuse large B-cell lymphoma (DLBCL). However, associations of comorbidity with lymphoma characteristics, treatment selection and lymphoma-specific mortality are less well known. Objective To examine the impact of comorbidity on DLBCL characteristics, treatment intent and cause of death. Methods We identified 3905 adult patients diagnosed with DLBCL 2007-2013 through the Swedish Lymphoma Register. We assessed comorbid disease history according to the Charlson comorbidity index (CCI). Comorbidity data and causes of death were collected through register linkage. Associations were estimated using multinomial regression and flexible parametric survival models. Results Overall, 45% of the patients (n = 1737) had a history of at least one comorbidity at DLBCL diagnosis (cardiovascular disease, diabetes and solid cancer were most frequent), and 997 (26%) had a CCI score of 2. The relative probability of presenting with poor performance status (PS > 2) was higher amongst comorbid patients [Relative Risk Ratio (RRR)(PS>2): 2.02, 95% CI: 1.63-2.51]. Comorbid patients had a substantially lower relative probability of receiving curative treatment (RRR: 0.48, 95% CI: 0.38-0.61). Amongst all patients, CCI 1 was associated with a significantly increased risk of all-cause and lymphoma-specific death after adjustments. Amongst patients selected for curative treatment, comorbidity was associated with an increased risk of all-cause death (HRCCI>1: 1.54, 95% CI: 1.32-1.80), but not with lymphoma-specific death (HRCCI>1: 1.05, 95% CI: 0.86-1.28). Conclusion Comorbidity is associated with inferior DLBCL outcome, mainly due to a lower likelihood of receiving treatment with curative intent. Possibly, more comorbid DLBCL patients could be treated with curative intent if comorbid conditions were optimized in parallel.

Published
2019
Full Text
View/download PDF

40. Six cycles of R-CHOP-21 are not inferior to eight cycles for treatment of diffuse large B-cell lymphoma: a Nordic Lymphoma Group Population-based Study

Author

Wästerlid, T., primary, Biccler, J.L., additional, Brown, P.N., additional, Bøgsted, M., additional, Enblad, G., additional, Mészáros Jørgensen, J., additional, Christensen, J.H., additional, Wahlin, B.E., additional, Smedby, K.E., additional, El-Galaly, T.C., additional, and Jerkeman, M., additional

Published
2018
Full Text
View/download PDF

41. Six cycles of R-CHOP-21 are not inferior to eight cycles for treatment of diffuse large B-cell lymphoma : a Nordic Lymphoma Group Population-based Study

Author

Wasterlid, T., Biccler, J. L., Brown, P. N., Bogsted, M., Enblad, Gunilla, Jorgensen, J. Meszaros, Christensen, J. H., Wahlin, B. E., Smedby, K. E., El-Galaly, T. C., Jerkeman, M., Wasterlid, T., Biccler, J. L., Brown, P. N., Bogsted, M., Enblad, Gunilla, Jorgensen, J. Meszaros, Christensen, J. H., Wahlin, B. E., Smedby, K. E., El-Galaly, T. C., and Jerkeman, M.

Published
2018
Full Text
View/download PDF

42. Six cycles of R-CHOP-21 are not inferior to eight cycles for treatment of diffuse large B-cell lymphoma:a Nordic Lymphoma Group Population-based Study

Author

Wästerlid, T, Biccler, J L, Brown, P N, Bøgsted, M, Enblad, G, Mészáros Jørgensen, J, Christensen, J H, Wahlin, B E, Smedby, K E, El-Galaly, T C, Jerkeman, M, Wästerlid, T, Biccler, J L, Brown, P N, Bøgsted, M, Enblad, G, Mészáros Jørgensen, J, Christensen, J H, Wahlin, B E, Smedby, K E, El-Galaly, T C, and Jerkeman, M

Published
2018

43. Is good clinical practice becoming poor clinical care?

Author

Le Gouill, S. Dreyling, M. Caballero, M.D. Andre, M. Doorduijn, J. Jurczak, W. Jerkeman, M. Ghia, P. Zinzani, P.-L. Da Silva, M.G. Dimopoulos, M. Trneny, M. Delarue, R. Walewski, J. Gisselbrecht, C. López-Guillermo, A. Rule, S.

Published
2017

46. DOSE-DENSE CHEMOIMMUNOTHERAPY AND CNS PROPHYLAXIS IN PATIENTS WITH HIGH-RISK DLBCL: A COMPARISON OF NORDIC CRY-04 AND CHIC STUDIES

Author

Leppä, S., primary, Joergensen, J., additional, de Nully Brown, P., additional, Fagerli, U., additional, Larsen, T.S., additional, Janes, R., additional, Mannisto, S., additional, Munksgaard, L., additional, Maisenhölder, M., additional, Vasala, K., additional, Meyer, P., additional, Jerkeman, M., additional, Björkholm, M., additional, Fluge, Ø., additional, Jyrkkiö, S., additional, Pedersen, L.M., additional, Eriksson, M., additional, and Holte, H., additional

Published
2017
Full Text
View/download PDF

48. IBRUTINIB VS TEMSIROLIMUS: THREE-YEAR FOLLOW-UP OF PATIENTS WITH PREVIOUSLY TREATED MANTLE CELL LYMPHOMA FROM THE PHASE 3, INTERNATIONAL, RANDOMIZED, OPEN-LABEL RAY STUDY

Author

Rule, S., primary, Jurczak, W., additional, Jerkeman, M., additional, Santucci Silva, R., additional, Rusconi, C., additional, Trneny, M., additional, Offner, F., additional, Caballero, D., additional, Joao, C., additional, Witzens-Harig, M., additional, Hess, G., additional, Bence-Bruckler, I., additional, Cho, S., additional, Thieblemont, C., additional, Zhou, W., additional, Henninger, T., additional, Goldberg, J.D., additional, Vermeulen, J., additional, and Dreyling, M., additional

Published
2017
Full Text
View/download PDF

50. MANTLE CELL LYMPHOMA OF MUCOSA-ASSOCIATED LYMPHOID TISSUE: A RETROSPECTIVE MULTICENTER OBSERVATIONAL STUDY OF THE EUROPEAN MANTLE CELL LYMPHOMA NETWORK

Author

Morello, L., primary, Rattotti, S., additional, Jerkeman, M., additional, van Meerten, T., additional, Krawczyk, K., additional, Moita, F., additional, Marino, D., additional, Ferrero, S., additional, Szymczyk, M., additional, Aurer, I., additional, El-Galaly, T.C., additional, Di Rocco, A., additional, Carli, G., additional, Defrancesco, I., additional, Giordano, L., additional, Carlo-Stella, C., additional, Dreyling, M., additional, Santoro, A., additional, and Arcaini, L., additional

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results